Medline ® Abstract for Reference 50
of 'Management of epilepsy and pregnancy'
50
TI
Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency.
AU
Cornelissen M, Steegers-Theunissen R, Kollée L, Eskes T, Motohara K, Monnens L
SO
Am J Obstet Gynecol. 1993;168(3 Pt 1):884.
OBJECTIVE:
The null hypothesis of this study is that extra vitamin K administered to pregnant women on a regimen of enzyme-inducing anticonvulsant therapy will not decrease the frequency of symptoms of vitamin K deficiency in their neonates.
STUDY DESIGN:
A multicenter case-control study was performed on 16 pregnant women on anticonvulsant therapy who received 10 mg of vitamin K1 daily from 36 weeks of pregnancy onward. Concentrations of PIVKA-II (protein induced by vitamin K absence for factor II) and of vitamin K1 were determined in cord blood and compared with those in 20 controls.
RESULTS:
In none of 17 cord samples was PIVKA-II detectable, compared with 13 of 20 in controls (chi 2, p<0.001). Median cord vitamin K1 level was 530 pg/ml compared with below detection limit in most controls.
CONCLUSIONS:
Antenatal vitamin K1 treatment decreases the frequency of vitamin K deficiency in neonates of mothers on anticonvulsant therapy.
AD
Department of Pediatrics, University Hospital Nijmegen, The Netherlands.
PMID